GetTopicDetailResponse(id=7738808044, topicName=GLP-1RAs, introduction=GLP-1RAs, content=null, image=null, comments=0, allHits=967, url=https://h5.medsci.cn/topic?id=8080, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=53415, tagList=[TagDto(tagId=53415, tagName=GLP-1RAs)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2259140, encodeId=f313225914066, content=<a href='/topic/show?id=7738808044' target=_blank style='color:#2F92EE;'>#GLP-1RAs#</a> <a href='/topic/show?id=e12f125e494e' target=_blank style='color:#2F92EE;'>#內鏡圍手術期#</a>, objectTitle=2025年美國消化內鏡學會關于胰高血糖素樣肽-1受體激動劑和鈉-葡萄糖協(xié)同轉運蛋白-2抑制劑患者內鏡圍手術期管理的立場聲明, objectType=article, longId=870448, objectId=a7d08e04483e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/patient-meeting-a-doctor-PAYSRMZ.jpg, objectUrl=/article/show_article.do?id=a7d08e04483e, replyNumber=0, likeNumber=39, createdTime=2025-04-04, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7d08e04483e, moduleTitle=2025年美國消化內鏡學會關于胰高血糖素樣肽-1受體激動劑和鈉-葡萄糖協(xié)同轉運蛋白-2抑制劑患者內鏡圍手術期管理的立場聲明, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a7d08e04483e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2246452, encodeId=50d22246452cd, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=2ad5104395dc' target=_blank style='color:#2F92EE;'>#糖尿病#</a></a> <a href='/topic/show?id=3ad9818917c' target=_blank style='color:#2F92EE;'>#肥胖#</a> <a href='/topic/show?id=7738808044' target=_blank style='color:#2F92EE;'>#GLP-1RAs#</a>, objectTitle=揭秘GLP-1RAs：降糖減重神藥的七大未解之謎, objectType=article, longId=858018, objectId=d7cc85801894, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241230/1735546972137_8538692.jpg, objectUrl=/article/show_article.do?id=d7cc85801894, replyNumber=0, likeNumber=94, createdTime=2025-01-03, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=d7cc85801894, moduleTitle=揭秘GLP-1RAs：降糖減重神藥的七大未解之謎, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d7cc85801894)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176271, encodeId=5c7521e627195, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲雙胍#</a> <a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a> <a href='/topic/show?id=7738808044' target=_blank style='color:#2F92EE;'>#GLP-1RAs#</a>, objectTitle=Front Public Health：六種GLP-1RAs治療中國2 型糖尿病患者二甲雙胍控制不佳的有效性和成本-效果, objectType=article, longId=806211, objectId=525c80621161, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221115/1668550106145_4754896.jpeg, objectUrl=/article/show_article.do?id=525c80621161, replyNumber=0, likeNumber=126, createdTime=2023-12-21, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=525c80621161, moduleTitle=Front Public Health：六種GLP-1RAs治療中國2 型糖尿病患者二甲雙胍控制不佳的有效性和成本-效果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=525c80621161)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯話題小助手
2020-05-29
